Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Director | November 24, 2025 | November 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date November 24, 2025 · Filed November 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $250.52 · Expires 2032-11-11 | Direct | 1,331 |
Reported balance
After 2025-11-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-24 · Grant · Acquired 1,331 · Balance 1,331 F1: Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date. |
| ResMed Common StockSEC Table I · non-derivative | Direct | 777 |
Reported balance
Holding disclosure · report date 2025-11-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 777 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 24, 2025 Filed Nov 26, 2025 17:29 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 1,331 | $250.52 Strike: $250.52 | $333,442.12 |
DisclosureSEC source: 0000943819-25-000180 · form4.xml · derivative · entry 2 Mowad-Nassar Nicole · CIK 0002084190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,331 Underlying: ResMed Common Stock · 1,331 shares Expires 2032-11-11 F1 · derivative.exercise_date: Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 19:42 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000177 · form4.xml · nonDerivative · entry 1 Mowad-Nassar Nicole · CIK 0002084190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 777 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 16:14 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 241 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-021161 · form4.xml · nonDerivative · entry 1 Mowad-Nassar Nicole · CIK 0002084190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.